ABOS

Over the past six months, Acumen Pharmaceuticals, Inc.'s stock has experienced volatility, with a 1-month change of -16.14% and a 3-month change of +9.96% as of September 22, 2026, while showing a year-to-date increase of 25.59% and a 107.03% increase over the past year. Key events include the Q2 2026 financial results on August 12, 2026, which reported an earnings per share (EPS) miss of -$0.45 against an estimated -$0.36 and a 'going concern' warning, impacting the stock despite a narrowed net loss. The company's participation in investor conferences and a virtual investor day in September 2026 aimed to generate investor interest. The ongoing anticipation of topline results from the Phase 2 ALTITUDE-AD trial for sabirnetug, expected in late 2026, has contributed to the stock's stability. Additionally, a director sold 32,300 shares in June 2026 after exercising options.